Independent global B2B platform
Expert in API & CDMO market
Direct contact between you and supplier

Find, compare & contact

Saxagliptin base (Saxagliptin) API Manufacturers

Real trade data

Filters

Reset current filters

Type
Production region
Qualifications
Country of origin
Contact suppliers

TOP RANKING

Located in:

India

Produced in:

India

Established in: 1984

MOQ: -

Employees: 2000+

Vertically integrated company

Largest producer of Montelukast in the world

USFDA & WHO GMP approved API plants

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • USDMF

  • WC

  • GMP

  • CoA

  • EDMF/ASMF

  • FDA

  • ISO9001

  • MSDS

  • BSE/TSE

HIGHLIGHTED

Located in:

China

Produced in:

China

Established in: 2008

MOQ: -

Employees: 300+

More than 150 patents based on independent intelligence

Expertise in anti-tumor, anti-diabetes and cardiovascular API and intermediates.

GMP facility with annual production capacity of 300M

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • GMP

  • CoA

Produced in:

China

Established in: 1987

MOQ: 1 kg

Employees: 50+

ISO 9001:2015 & SGS audited supplier

One-stop CDMO Solutions for APl and Key intermediates

Specialized in APIs & Pharmaceutical Intermediates for 37 years

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • GMP

  • USDMF

  • CoA

  • ISO9001

  • MSDS

Produced in:

China

Established in: 2011

MOQ: 10 g

Employees: 10+

Fast Response and Good Communication

Willingness To Start From Small

Flexible Payment Terms

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • CoA

  • BSE/TSE

  • MSDS

Distributor

Produced in:

World

Established in: 2005

MOQ: -

Employees: 200+

Portfolio of over 2,000 APIs

Precise quality control

End-to-end global regulatory support

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • USDMF

  • CEP

  • GMP

  • CoA

  • MSDS

  • BSE/TSE

Located in:

China

Produced in:

China

Established in: 2004

MOQ: -

Employees: 700+

has international standard facilities for API

specialized in active pharmaceutical ingredients development and GMP manufacturing

has 3 manufacturing plants

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • CoA

  • MSDS

  • BSE/TSE

  • USDMF

Located in:

China

Produced in:

China

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • USDMF

  • CoA

Located in:

China

Produced in:

China

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • coa

Producer

Produced in:

Unknown

Established in: 1944

MOQ: -

Employees: 4,000

14 international API plant sites

Portfolio of 350+ APIs

Teva is among the world’s largest generic drug/API manufacturers

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • USDMF

  • CoA

Located in:

India

Producer

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • USDMF

  • CoA

Located in:

India

Producer

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • GMP

  • WC

  • CoA

  • USDMF

Located in:

India

Producer

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • USDMF

  • CoA

Located in:

China

Produced in:

China

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • coa

Located in:

India

Producer

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • USDMF

  • + 0

All certificates

  • WC

  • CoA

  • GMP

  • USDMF

How does it work?

1
Register for free
icon

You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry

2
Start sourcing
icon

Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only

3
Send inquiries
icon

Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week

4
Get quotation
icon

Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news

5
Arrange agreement
icon

Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module

Looking for Saxagliptin API 361442-04-8?

Description:
Here you will find a list of producers, manufacturers and distributors of Saxagliptin. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Saxagliptin 
Synonyms:
Onglyza , Saxagliptin Hydrochloride , Saxagliptin Hydrochloride Dihydrate , Saxagliptin Monohydrate , Saxagliptin Base  
Cas Number:
361442-04-8 
DrugBank number:
DB06335 
Unique Ingredient Identifier:
8I7IO46IVQ

About Saxagliptin

Want to know more about Saxagliptin? Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.

You can ask the supplier for more technical information about the product.

Saxagliptin is a type of DPP4-Inhibitors


DPP4-Inhibitors, or dipeptidyl peptidase-4 inhibitors, belong to the subcategory of pharmaceutical active ingredients known for their therapeutic role in managing type 2 diabetes mellitus. These inhibitors work by targeting and inhibiting the action of the enzyme dipeptidyl peptidase-4 (DPP4) in the body.

DPP4 is responsible for breaking down incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP4, DPP4-Inhibitors enhance the levels and activity of these hormones. GLP-1 and GIP play crucial roles in regulating blood sugar levels by stimulating insulin release, inhibiting glucagon secretion, and slowing down gastric emptying.

The main advantage of DPP4-Inhibitors is their ability to improve glycemic control without the risk of hypoglycemia, which is a common side effect of some other diabetes medications. They are typically used as an adjunct therapy in combination with other antidiabetic agents, such as metformin, to achieve optimal glucose management.

Commonly prescribed DPP4-Inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin. These drugs are available in oral tablet formulations, allowing for convenient administration. They have shown efficacy in lowering HbA1c levels and have a favorable safety profile.

It is important to note that DPP4-Inhibitors are not suitable for individuals with type 1 diabetes or those with a history of pancreatitis. As with any medication, there may be potential side effects, such as upper respiratory tract infections, headache, and gastrointestinal discomfort, which should be discussed with a healthcare professional.

In conclusion, DPP4-Inhibitors are a subcategory of pharmaceutical APIs that act by inhibiting the enzyme DPP4, thereby enhancing the effects of incretin hormones involved in glucose regulation. They are widely used in the management of type 2 diabetes mellitus, offering glycemic control benefits with a reduced risk of hypoglycemia.


Saxagliptin (DPP4-Inhibitors), classified under Anti-diabetics


Anti-diabetics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are a group of compounds designed to manage and treat diabetes mellitus, a chronic metabolic disorder characterized by high blood sugar levels. These medications play a vital role in controlling diabetes and preventing complications associated with the disease.

Anti-diabetics encompass a wide range of drug classes, including biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Each class works through different mechanisms to regulate blood sugar levels and improve insulin sensitivity.

Biguanides, such as metformin, reduce glucose production by the liver and enhance insulin sensitivity in peripheral tissues. Sulfonylureas, like glipizide, stimulate insulin secretion from pancreatic beta cells. Thiazolidinediones, including pioglitazone, improve insulin sensitivity in muscle and adipose tissues. DPP-4 inhibitors, such as sitagliptin, increase insulin release and inhibit glucagon secretion. SGLT2 inhibitors, like dapagliflozin, decrease renal glucose reabsorption, leading to increased urinary glucose excretion. GLP-1 receptor agonists, such as exenatide, enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.

These anti-diabetic APIs serve as the foundational ingredients for the formulation of various oral tablets, capsules, and injectable medications used in the treatment of diabetes. By targeting different aspects of glucose regulation, they help patients achieve and maintain optimal blood sugar levels, thus reducing the risk of diabetic complications, such as cardiovascular disease, neuropathy, and nephropathy.

It is crucial for healthcare professionals to prescribe and administer these anti-diabetic medications appropriately, considering factors like the patient's medical history, co-existing conditions, and potential drug interactions. Regular monitoring of blood glucose levels and close medical supervision are necessary to ensure effective diabetes management.

In conclusion, anti-diabetics form a critical category of pharmaceutical APIs used for the treatment of diabetes. These compounds, encompassing various drug classes, work through distinct mechanisms to regulate blood sugar levels and improve insulin sensitivity. By facilitating glucose control, anti-diabetic APIs help mitigate the risk of complications associated with diabetes mellitus, ultimately promoting better health outcomes for patients.



Saxagliptin manufacturers | traders | suppliers

We have 14 companies offering Saxagliptin produced in 4 different countries.

Get in contact with the supplier of your choice:

  • Morepen Laboratories Ltd. from India, product country of origin India
  • Tianjin Pharmacn Medical Technology Co., ltd from China, product country of origin China
  • Sinoway industrial Co.,Ltd from China, product country of origin China
  • Shandong Octagon Chemicals Limited from China, product country of origin China
  • LGM Pharma from United States, product country of origin World
  • Zhejiang Hengkang Pharmaceutical Co. Ltd from China, product country of origin China
  • Beijing Huikang Boyuan from China, product country of origin China
  • Tianjin Minxiang from China, product country of origin China
  • Teva API from Israel, product country of origin Unknown
  • Raks Pharma from India, product country of origin India
  • MSN Pharma from India, product country of origin India
  • Mylan from India, product country of origin India
  • Shaoxing Hantai Pharma from China, product country of origin China
  • Cipla from India, product country of origin India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.